Assessing potential of psilocybin for depressive disorders
The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: There has been increasing interest in the role psilocybin may play in the treatment of depressive disorders. Several clinical trials have shown psilocybin to have efficacy in reducing symptoms of depression. AREASCOVERED: We discuss the current understanding of psilocybin's therapeutic mechanism of action and review existing clinical data investigating psilocybin as a novel therapeutic agent for the treatment of depression. EXPERT OPINION: There is still much unknown regarding the risks of psilocybin treatment. When weighing the known risks and benefits of psilocybin treatment against those found in existing standards of care, among patients with depression, patients with treatment-resistant depression (TRD) may be the most suitable candidates for psilocybin treatment at this time.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 3×
“Numerous studies have investigated psilocybin as a novel therapeutic compound for the treatment of depression [10–14], and favorable findings from a recent phase IIb clinical trial have paved the way for the world’s first phase 3 clinical trial of psilocybin for TRD [15].”
BackgroundSelf-citationEpidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States
Hasin, D. S., Sarvet, A. L., Meyers, J. L., Saha, T. D., Ruan, W. J., Stohl, M., & Grant, B. F. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.4602 · Cited by 1,737 · cited 1×
“Recent reports found that Major Depressive Disorder (MDD) was diagnosed in 10% of the general population in the United States in the past 12 months [3], and about one in three patients seeking treatment for MDD fail to respond to+ adequate trials of at least two antidepressant medications,…”
BackgroundRoss, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 2×
“Multiple clinical trials have found psilocybin to be associated with persistent, positive effects on mood and behavior [21,22], leading to scientific enthusiasm about its potential to treat depression.”
BackgroundCarhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 3×
“In 2016, Carhart-Harris et al. [11] published an open-label, single-arm pilot study investigating the feasibility of psilocybin for TRD. Participants received two oral doses of psilocybin, 10 and 25 mg, 7 days apart with psychological support.”
BackgroundDepression Is the Leading Cause of Disability Around the World
Friedrich, M. J. (2017) · JAMA · doi:10.1001/jama.2017.3826 · Cited by 1,459
Trial of Psilocybin versus Escitalopram for Depression
Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032994 · Cited by 1,391 · cited 3×
“Although the 2021 study by Carhart-Harris et. al [14]. was not designed as a non-inferiority trial, and would have been under-powered as such, it is notable that the study found no difference in primary outcome between the psilocybin treatment and treatment-as-usual with a known efficacious and…”
BackgroundResultEffects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301 · cited 2×
“The same year, Davis et al. [13] published a randomized controlled clinical trial ( N = 24) assessing psilocybin’s effect on depression scores in participants with MDD. Participants received two psilocybin sessions (session 1 dosed at 20 mg/ 70 kg and session 2 dosed at 30 mg/70 kg) about 1.5 weeks”
BackgroundInfluentialSelf-citationPsychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206 · cited 1×
“In 2011, Grob et al. [49] published a double-blind, within-subject, randomized, placebo-controlled trial ( N = 12) investigating the effects of psilocybin in patients with anxiety related to advanced-stage cancer.”
BackgroundSingle-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206443 · Cited by 1,167 · cited 5×
“Several studies demonstrated a rapid (i.e. within 1 or 2 days) reduction in depressive symptoms [12,37,42], even among patients who were concurrently taking SSRI medications [52].”
BackgroundInfluentialSelf-citationPsilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970 · cited 1×
“A 6-month follow-up [51] found statistically significant reductions in depressive symptoms in the first 5 weeks post-treatment, which remained significant at 3 and 6 months.”
BackgroundPsilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
Self-citationRoseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00974 · Cited by 808
Long-term follow-up of psilocybin-facilitated smoking cessation
Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2016.1170135 · Cited by 696
Self-citationWatts, R., Day, C., Krzanowski, J., Nutt, D., & Carhart-Harris, R. (2017) · Journal of Humanistic Psychology · doi:10.1177/0022167817709585 · Cited by 589
Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W., & Griffiths, R. R. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116662634 · Cited by 553
Self-citationMadsen, M. K., Fisher, P. M., Burmester, D., Dyssegaard, A., Stenbæk, D. S., Kristiansen, S., Johansen, S. S., Lehel, S., Linnet, K., Svarer, C., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0324-9 · Cited by 517 · cited 2×
“Psilocin is the pharmacologically active compound metabolized from psilocybin, and preferentially binds the 5-HT2a receptor (5-HT2aR) on pyramidal cells in cortical and deep cortical layers, leading to glutaminergic signaling [18,19].”
BackgroundJohnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.010 · Cited by 506 · cited 1×
“Additional evidence for 5-HT2aR as the primary receptor mechanism comes from human and nonhuman antagonist studies, 5-HT2aR knockout nonhuman studies, and human and nonhuman data showing strong correlations between 5-HT2aR affinity and potency across many classic psychedelic compounds [20].”
BackgroundSelf-citationPsychedelics promote plasticity by directly binding to BDNF receptor TrkB
Moliner, R., Girych, M., Brunello, C. A., Kovaleva, V., Biojone, C., Enkavi, G., Antenucci, L., Kot, E. F., Goncharuk, S. A., Kaurinkoski, K., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01316-5 · Cited by 478 · cited 1×
“Preclinical data suggest neuroplastic effects may be related to psilocy-bin’s strong affinity for TrkB (the receptor for BDNF), as well as mTOR and serotonergic signaling [23,24], though this has only been studied in animal models and has not been demonstrated in humans.”
BackgroundPsilocybin-Occasioned mystical experiences in the treatment of tobacco addiction.
Garcia-Romeu, A., Griffiths, R., & Johnson, M. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107121331 · Cited by 476
Self-citationThe pharmacology of psilocybin
Passie, T., Seifert, J., Schneider, U., & Emrich, H. M. (2002) · Addiction Biology · doi:10.1080/1355621021000005937 · Cited by 465 · cited 1×
“Psilocybin ( 4-phosphoryloxy-N,N-dimethyltryptamine ) is a naturally-occurring psychoactive tryptamine-based alkaloid found in several species of mushrooms across the world Table 1 [16].”
BackgroundCrystal Structure of an LSD-Bound Human Serotonin Receptor
Wacker, D., Wang, S., McCorvy, J. D., Betz, R. M., Venkatakrishnan, A. J., Levit, A., Lansu, K., Schools, Z. L., Che, T., Nichols, D. E., et al. (2017) · Cell · doi:10.1016/j.cell.2016.12.033 · Cited by 457
Neuroticism as a common dimension in the internalizing disorders
Griffith, J. W., Zinbarg, R. E., Craske, M. G., Mineka, S., Rose, R. D., Waters, A. M., & Sutton, J. M. (2010) · Psychological Medicine · doi:10.1017/s0033291709991449 · Cited by 440 · cited 1×
“Neuroticism is thought to be a core feature of internalizing psychopathologies, such as depression [32], and psilocybin treatment has been found to significantly reduce neuroticism scores at both 3-month [33] and 6-month follow-up [34] in clinical trials.”
BackgroundGukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211073759 · Cited by 425
Self-citationThe Impact of Treatment-Resistant Depression on Health Care Utilization and Costs
Crown, W. H., Finkelstein, S., Berndt, E. R., Ling, D., Poret, A. W., Rush, A. J., & Russell, J. M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1102 · Cited by 386
Hendricks, P. S., Thorne, C. B., Clark, C. B., Coombs, D. W., & Johnson, M. W. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565653 · Cited by 381
Self-citationHesselgrave, N., Troppoli, T. A., Wulff, A. B., Cole, A. B., & Thompson, S. M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2022489118 · Cited by 378 · cited 1×
“Preclinical studies have shown persistent anti-depressive effects of psilocybin in mice even after blocking the 5-HT2aR [44], and a recent case report highlighted a psilocybin trial participant who continued to take a potent 5-HT2aR antagonist (Trazodone), but still had a rapid, robust, and…”
BackgroundAgin-Liebes, G. I., Malone, T., Yalch, M. M., Mennenga, S. E., Ponté, K. L., Guss, J., Bossis, A. P., Grigsby, J., Fischer, S., & Ross, S. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119897615 · Cited by 360
von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., et al. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2022.101809 · Cited by 354
The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects
Olson, D. E. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00192 · Cited by 329 · cited 1×
“The extent to which such subjective experiences are necessary for therapeutic benefit is an area of active debate [43].”
BackgroundExploratory randomized controlled trial evaluating the impact of a waiting list control design
Cunningham, J. A., Kypri, K., & McCambridge, J. (2013) · BMC Medical Research Methodology · doi:10.1186/1471-2288-13-150 · Cited by 321 · cited 1×
“For example, while a waitlist control design may help address issues of expectancy, it has also been shown to over-estimate treatment effects [55].”
BackgroundJohnston, K. M., Powell, L. C., Anderson, I. M., Szabo, S., & Cline, S. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.06.045 · Cited by 321
Psychedelics not linked to mental health problems or suicidal behavior: A population study
Johansen, P.-Ø., & Krebs, T. S. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114568039 · Cited by 302
Fekadu, A., Wooderson, S. C., Markopoulo, K., Donaldson, C., Papadopoulos, A., & Cleare, A. J. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.10.014 · Cited by 299
Paradoxical trafficking and regulation of 5-HT2A receptors by agonists and antagonists
Gray, J. A., & Roth, B. L. (2001) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00623-2 · Cited by 296
Psychedelic therapy for smoking cessation: qualitative analysis of participant accounts
Noorani, T., Garcia-Romeu, A., Swift, T. C., Griffiths, R. R., & Johnson, M. W. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118780612 · Cited by 285
Self-citationEffects of psilocybin therapy on personality structure
Erritzoe, D., Roseman, L., Nour, M. M., MacLean, K., Kaelen, M., Nutt, D. J., & Carhart‐Harris, R. L. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12904 · Cited by 267
Griffiths, R. R., Hurwitz, E. S., Davis, A. K., Johnson, M. W., & Jesse, R. (2019) · PLOS ONE · doi:10.1371/journal.pone.0214377 · Cited by 247
Self-citationAday, J. S., Heifets, B. D., Pratscher, S. D., Bradley, E., Rosen, R., & Woolley, J. D. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06123-7 · Cited by 237
Béïque, J.-C., Imad, M., Mladenovic, L., Gingrich, J. A., & Andrade, R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700436104 · Cited by 229 · cited 1×
“Psilocin is the pharmacologically active compound metabolized from psilocybin, and preferentially binds the 5-HT2a receptor (5-HT2aR) on pyramidal cells in cortical and deep cortical layers, leading to glutaminergic signaling [18,19].”
BackgroundLetheby, C. (2021) · Oxford University Press eBooks · doi:10.1093/med/9780198843122.001.0001 · Cited by 215
Psychedelic-inspired drug discovery using an engineered biosensor
Dong, C., Ly, C., Dunlap, L. E., Vargas, M. V., Sun, J., Hwang, I.-W., Azinfar, A., Oh, W. C., Wetsel, W. C., Olson, D. E., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.043 · Cited by 213
Swift, T. C., Belser, A. B., Agin-Liebes, G., Devenot, N., Terrana, S., Friedman, H. L., Guss, J., Bossis, A. P., & Ross, S. (2017) · Journal of Humanistic Psychology · doi:10.1177/0022167817715966 · Cited by 195
Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance
Wolff, M., Evens, R., Mertens, L. J., Koslowski, M., Betzler, F., Gründer, G., & Jungaberle, H. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00005 · Cited by 194
The promises and perils of psychedelic pharmacology for psychiatry
McClure-Begley, T. D., & Roth, B. L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00421-7 · Cited by 194
Must Psilocybin Always “Assist Psychotherapy”?
Goodwin, G. M., Malievskaia, E., Fonzo, G. A., & Nemeroff, C. B. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20221043 · Cited by 189
Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication
Goodwin, G. M., Croal, M., Feifel, D., Kelly, J. R., Marwood, L., Mistry, S., O’Keane, V., Peck, S. K., Simmons, H., Sisa, C., et al. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01648-7 · Cited by 187 · cited 4×
“…had a statistically significant reduction in depression score at 3-week follow-up compared to those receiving 1 mg. Finally, in 2023 Goodwin et al. [52] published a phase II, exploratory, open-label trial ( N = 19) specifically assessing the efficacy of psilocybin among participants with TRD who…”
BackgroundInfluentialBonson, K. R., Buckholtz, J. W., & Murphy, D. L. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00145-4 · Cited by 170
Sloshower, J., Skosnik, P. D., Safi-Aghdam, H., Pathania, S., Syed, S., Pittman, B., & D’Souza, D. C. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231154852 · Cited by 165
Brown, S., Rittenbach, K., Cheung, S., McKean, G., MacMaster, F. P., & Clement, F. (2019) · The Canadian Journal of Psychiatry · doi:10.1177/0706743719828965 · Cited by 151
Davis, A. K., Clifton, J. M., Weaver, E. G., Hurwitz, E. S., Johnson, M. W., & Griffiths, R. R. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120916143 · Cited by 146
Self-citationThe Cost Consequences of Treatment-Resistant Depression
Russell, J. M., Hawkins, K., Ozminkowski, R. J., Orsini, L., Crown, W. H., Kennedy, S., Finkelstein, S., Berndt, E., & Rush, A. J. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0309 · Cited by 117
Consciousness, Religion, and Gurus: Pitfalls of Psychedelic Medicine
Johnson, M. W. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00198 · Cited by 114
Self-citationPsychedelics and psychotherapy: Cognitive-behavioral approaches as default
Yaden, D. B., Earp, D., Graziosi, M., Friedman-Wheeler, D., Luoma, J. B., & Johnson, M. W. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.873279 · Cited by 110 · cited 1×
“It is unlikely there will be a one size fits all therapeutic approach that helps participants across all diagnostic presentations and personalities, but response rates and durability of response is likely to be responsive to educational and insight-oriented psychological support [59–61].”
BackgroundSelf-citationSertraline-induced desensitization of the serotonin 5HT-2 receptor transmembrane signaling system
Sanders‐Bush, E., Breeding, M., Knoth, K. M., & Tsutsumi, M. (1989) · Psychopharmacology · doi:10.1007/bf00634454 · Cited by 97
LSD-stimulated behaviors in mice require β-arrestin 2 but not β-arrestin 1
Rodriguiz, R. M., Nadkarni, V., Means, C. R., Pogorelov, V. M., Chiu, Y.-T., Roth, B. L., & Wetsel, W. C. (2021) · Scientific Reports · doi:10.1038/s41598-021-96736-3 · Cited by 94
Yamauchi, M., Miyara, T., Matsushima, T., & Imanishi, T. (2005) · Brain Research · doi:10.1016/j.brainres.2005.10.075 · Cited by 89
Costa, P. T., & McCrae, R. R. (2000) · Oxford University Press eBooks · doi:10.1037/10520-172 · Cited by 82
The effects of psychotomimetic drugs on primary suggestibility
Sjoberg, B. M., & Hollister, L. E. (1965) · Psychopharmacology · doi:10.1007/bf00407857 · Cited by 80
On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review
Zeifman, R. J., Singhal, N., Breslow, L., & Weissman, C. R. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00024 · Cited by 73
Psychedelics and psychotherapy
Nayak, S., & Johnson, M. W. (2021) · Pharmacopsychiatry · doi:10.1055/a-1312-7297 · Cited by 71 · cited 1×
“It is unlikely there will be a one size fits all therapeutic approach that helps participants across all diagnostic presentations and personalities, but response rates and durability of response is likely to be responsive to educational and insight-oriented psychological support [59–61].”
BackgroundSelf-citationAntidepressant Effects of Psilocybin in the Absence of Psychedelic Effects
Rosenblat, J. D., Leon-Carlyle, M., Ali, S., Husain, M. I., & McIntyre, R. S. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20220835 · Cited by 62
Husain, M. I., Blumberger, D. M., Castle, D. J., Ledwos, N., Fellows, E., Jones, B. D. M., Ortiz, A., Kloiber, S. M., Wang, W., Rosenblat, J. D., et al. (2023) · BJPsych Open · doi:10.1192/bjo.2023.535 · Cited by 57
Agin-Liebes, G., Ekman, E., Anderson, B., Malloy, M., Haas, A., & Woolley, J. (2024) · Journal of Humanistic Psychology · doi:10.1177/00221678211022949 · Cited by 51
Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression
Weiss, B., Ginige, I., Shannon, L., Giribaldi, B., Murphy-Beiner, A., Murphy, R., Baker-Jones, M., Martell, J., Nutt, D. J., Carhart-Harris, R. L., et al. (2024) · Psychological Medicine · doi:10.1017/s0033291723001514 · Cited by 40
Control Conditions in Randomized Trials of Psychedelics: An ACTTION Systematic Review
Nayak, S. M., Bradley, M. K., Kleykamp, B. A., Strain, E. C., Dworkin, R. H., & Johnson, M. W. (2023) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.22r14518 · Cited by 39
Self-citationThe Effects of LSD on Body Sway Suggestibility in a Group of Hospital Patients
Middlefell, R. (1967) · British Journal of Psychiatry · doi:10.1192/bjp.113.496.277 · Cited by 27
Davis, A. K., Levin, A. W., Nagib, P. B., Armstrong, S. B., & Lancelotta, R. L. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-068884 · Cited by 21 · cited 1×
“To this point, a recent protocol [58] utilizes a study design in which clinical ratings are completed following preparatory psychotherapy sessions and prior to first psilocybin dosing, to account for a change that might occur due to therapy.”
Psilocybin for Depression: From Credibility to Feasibility, What’s Missing?
Munafò, A., Arillotta, D., Mannaioni, G., Schifano, F., Bernardini, R., & Cantarella, G. (2022) · Pharmaceuticals · doi:10.3390/ph16010068 · Cited by 15
The molecular basis of the antidepressant action of the magic mushroom extract, psilocin
Zanjani, A. A. H., Nguyen, T. Q. T., Jacobsen, L., & Khandelia, H. (2023) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2023.140914 · Cited by 7
LSD subcultures: Acidoxy versus orthodoxy.
Gioscia, V. (1969) · American Journal of Orthopsychiatry · doi:10.1111/j.1939-0025.1969.tb00638.x · Cited by 5
Research works printed but not linked: 2
- Agrawal M Emanuel E Richards B et al. Assessment of psilocybin therapy for patients with cancer and major depression disorder. JAMA Oncol [Internet]. 2023 [cited 2023 Jun 5]; Available from: https://jamanetwork.com/journals/jamaoncology/fullarticle/2803623.
- Paglia C. Cults and cosmic consciousness: religious vision in the American. Arion. 2003;10(3): 1–111.
Cited by
Hashimoto, K. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01770-7 · Cited by 62
Kwon, K. J., Kim, H. Y., Han, S., & Shin, C. Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111338 · Cited by 25
Beyond psychedelics: set and setting in general psychiatric practice
Kozak, Z., & Miller, C. W. T. (2024) · International Review of Psychiatry · doi:10.1080/09540261.2024.2419662 · Cited by 14
“…(Agrawal et al., 2023; Carhart-Harris et al., 2021; Carhart-Harris et al., 2016; Goodwin et al., 2022; Goodwin et al., 2023; Griffiths et al., 2016; Kozak et al., 2023; Ross et al., 2016), anxiety (Griffiths et al., 2016; Grob et al., 2011; Ross et al., 2016), post-traumatic stress disorder (PTSD)…”
Self-citationHilal, F. F., Jeanblanc, J., Deschamps, C., Naassïla, M., Pierrefiche, O., & Hamida, S. B. (2024) · Journal of Neural Transmission · doi:10.1007/s00702-024-02757-3 · Cited by 9
“…their potential as effective and long-lasting treatments for a wide range of neuropsychiatric diseases, including depression, PTSD and addiction (Mithoefer et al. 2013; Noller et al. 2018; Kozak et al. 2023; Jaster and González-Maeso 2023; Wojtas and Gołembiowska 2023; Barksdale et al. 2024).”
Innovations in group-based psilocybin-assisted therapy of major depression in patients with cancer
Thrul, J., Kozak, Z., Carducci, M. A., Garcia‐Romeu, A., & Yaden, D. B. (2024) · Cancer · doi:10.1002/cncr.35127 · Cited by 6
Self-citation
Metadata
- Authors
- Kozak, Z., Johnson, M. W., & Aaronson, S. T.
- Affiliations
- University of Maryland, Baltimore (US)
- Johns Hopkins University (US)
- Corresponding author
- Aaronson, Scott T.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2023-10-03
- Volume
- 32
- Issue
- 10
- Pages
- 887-900
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W4387866078
- Cited by
- 11
- References
- 74
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 6 · 2023: 1
- FWCI
- 0.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Investigational Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- psilocybin, depression, treatment-resistant depression, psychedelic therapy, clinical trials, benefits and risks, antidepressant efficacy
- MeSH terms
- Hallucinogens, Humans, Psilocybin, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.